Skip to main content
main-content

08-06-2021 | ASCO 2021 | Conference coverage | Video

Three-weekly cabazitaxel not ruled out as first-line option for metastatic breast cancer

Amit Bahl explains why 3-weekly cabazitaxel is still a valid option for treatment-naïve, HER2-negative, metastatic breast cancer even though the CONCEPT trial failed to show its superiority over weekly paclitaxel in this setting (7:14).

2021 ASCO Annual Meeting coverage

Access news and expert commentary from the 2021 ASCO Annual Meeting

Image Credits